Good day, everyone, and welcome to Pfizer's third quarter 2024 earnings conference call. Today's call is being recorded. At ...

Pfizer reported an adjusted EPS of $1.06, exceeding estimates by over 72%. Revenue reached $17.7 billion, marking a 32% year ...

Pfizer (PFE) stock fell even as the company beat forecasts with its Q3 results and increased its full-year outlook.Find out ...

Pfizer (PFE) stock gained after the company beat estimates with its Q3 2024 financials and raised its full-year guidance ...

Pfizer, Sanofi and others report Q3 beats; AbbVie, Roche and Novartis strike big deals; the 2024 presidential election looms; ...

CEO Albert Bourla, who is under attack from activist investor Starboard Value, got a much-needed victory on Tuesday as Pfizer ...

Pfizer’s third-quarter revenue and adjusted profit exceeded expectations, driven by strong sales of its Covid vaccine and ...

Morgan Stanley analyst Terence Flynn maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $30.00.

Pfizer reports Q3 EPS of $1.06, surpassing $0.62 consensus, with revenue up 31% to $17.7 billion. Growth driven by Paxlovid, ...

Pfizer Inc (PFE) reports a 32% operational revenue growth and raises full-year guidance, despite challenges in COVID-19 ...

Reports Q3 revenue $17.7B, consensus $14.95B. Dr. Albert Bourla, Chairman and Chief Executive Officer, stated: “We delivered another ...

Pfizer (PFE) delivered earnings and revenue surprises of 65.62% and 16.53%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?